Immunologic Research

, Volume 65, Issue 1, pp 55–65 | Cite as

Adjuvants- and vaccines-induced autoimmunity: animal models

  • Jiram Torres Ruiz
  • Luis Luján
  • Miri Blank
  • Yehuda Shoenfeld
Environment and Autoimmunity

Abstract

The emergence of autoimmunity after vaccination has been described in many case reports and series. Everyday there is more evidence that this relationship is more than casual. In humans, adjuvants can induce non-specific constitutional, musculoskeletal or neurological clinical manifestations and in certain cases can lead to the appearance or acceleration of an autoimmune disease in a subject with genetic susceptibility. The fact that vaccines and adjuvants can trigger a pathogenic autoimmune response is corroborated by animal models. The use of animal models has enabled the study of the effects of application of adjuvants in a homogeneous population with certain genetic backgrounds. In some cases, adjuvants may trigger generalized autoimmune response, resulting in multiple auto-antibodies, but sometimes they can reproduce human autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome, autoimmune thyroiditis and antiphospholipid syndrome and may provide insights about the potential adverse effects of adjuvants. Likewise, they give information about the clinical, immunological and histologic characteristics of autoimmune diseases in many organs, especially secondary lymphoid tissue. Through the description of the physiopathological characteristics of autoimmune diseases reproduced in animal models, new treatment targets can be described and maybe in the future, we will be able to recognize some high-risk population in whom the avoidance of certain adjuvants can reduce the incidence of autoimmune diseases, which typically results in high morbidity and mortality in young people. Herein, we describe the main animal models that can reproduce human autoimmune diseases with emphasis in how they are similar to human conditions.

Keywords

Adjuvants Vaccines Autoimmunity Pristane Alum Squalene 

References

  1. 1.
    Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492–503.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ahmed SS, Schur PH, Macdonald NE, Steinman L, Narcolepsy. A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun. 2014;50:1–11.CrossRefPubMedGoogle Scholar
  3. 3.
    Fournie GJ, Mas M, Cautain B, et al. Induction of autoimmunity through bystander effects. Lessons from immunological disorders induced by heavy metals. J Autoimmun. 2001;16(3):319–26.CrossRefPubMedGoogle Scholar
  4. 4.
    Guimaraes LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;100:190–209.CrossRefPubMedGoogle Scholar
  5. 5.
    Cruz-Tapias P, Agmon-Levin N, Israeli E, Anaya JM, Shoenfeld Y. Autoimmune (auto-inflammatory) syndrome induced by adjuvants (ASIA)—animal models as a proof of concept. Curr Med Chem. 2013;20:4030–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Whitehouse M. Oily adjuvants and autoimmunity: Now time for reconsideration? Lupus. 2012;21:217–22.CrossRefPubMedGoogle Scholar
  7. 7.
    Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82:9.Google Scholar
  8. 8.
    Hoffmann MH, Tuncel J, Skriner K, et al. The rheumatoid arthritis-associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritis. J Immunol. 2007;179(11):7568–76.CrossRefPubMedGoogle Scholar
  9. 9.
    Platica M, Bojko C, Steiner G, Hollander VP. Effect of subcutaneously administered 2,6,10,14-tetramethylpentadecane on plasmacytoma growth. Cancer Res. 1980;40:2229–33.PubMedGoogle Scholar
  10. 10.
    Bizjak M, Selmi C, Praprotnik S, et al. Silicone implants and lymphoma: the role of inflammation. J Autoimmun. 2015;65:64–73.CrossRefPubMedGoogle Scholar
  11. 11.
    Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease. Clin Rev Allergy Immunol. 2011;41(2):163–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Favoino E, Favia EI, Digiglio L, Racanelli V, Shoenfeld Y, Perosa F. Effects of adjuvants for human use in systemic lupus erythematosus (SLE)-prone (New Zealand black/New Zealand white) F1 mice. Clin Exp Immunol. 2012;175:32–40.CrossRefGoogle Scholar
  13. 13.
    Soldevilla HF, Briones SFR, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus. 2012;21:4.CrossRefGoogle Scholar
  14. 14.
    Agmon-Levin N, Arango MT, Kivity S, et al. Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model. J Autoimmun. 2014;54:21–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Holmdahl R, Lorentzen JC, Lu S, et al. Arthritis induced in rats with non-immunogenic adjuvants as models for rheumatoid arthritis. Immunol Rev. 2001;184:19.CrossRefGoogle Scholar
  16. 16.
    Salemo S, D’Amelio R. Could autoimmunity be induced by vaccination? Int Rev Immunol. 2010;29:247–69.CrossRefGoogle Scholar
  17. 17.
    Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA. 1994;271(20):1602–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Cohen AD, Shoenfeld Y. Vaccine-induced autoimmunity. J Autoimmun. 1996;9(6):699–703.CrossRefPubMedGoogle Scholar
  19. 19.
    Ropper AH, Victor M. Influenza vaccination and the Guillain–Barré syndrome. N Engl J Med. 1998;339(25):1845–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Tishler M, Shoenfeld Y. Vaccination may be associated with autoimmune diseases. Isr Med Assoc J. 2004;6(7):430–2.PubMedGoogle Scholar
  21. 21.
    Praprotnik S, Sodin-Semrl S, Tomsic M, Shoenfeld Y. The curiously suspicious: infectious disease may ameliorate an ongoing autoimmune destruction in systemic lupus erythematosus patients. J Autoimmun. 2008;30(1–2):37–41.CrossRefPubMedGoogle Scholar
  22. 22.
    Shoenfeld Y, Agmon-Levin N. ASIA Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun. 2013;47:1–16.CrossRefPubMedGoogle Scholar
  24. 24.
    Hall SW, Cooke A. Autoimmunity and inflammation: murine models and translational studies. Mamm Genome. 2011;22(7–8):377–89.CrossRefPubMedGoogle Scholar
  25. 25.
    Rose NR. The adjuvant effect in infection and autoimmunity. Clin Rev Allergy Immunol. 2008;34(3):279–82.CrossRefPubMedGoogle Scholar
  26. 26.
    Vladutiu AO, Rose N. Autoimmune murine thyroiditis relation to histocompatibility (H-2) type. Science. 1971;174(4014):1137–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Lujan L, Pérez M, Salazar E, et al. Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA syndrome) in commercial sheep. Immunol Res. 2013;56(2–3):317–24.CrossRefPubMedGoogle Scholar
  28. 28.
    Wester L, Olofsson P, Ibrahim SM, Holmdahl R. Chronicity of pristane-induced arthritis in rats is controlled by genes on chromosome 14. J Autoimmun. 2003;21(4):305–13.CrossRefPubMedGoogle Scholar
  29. 29.
    Holm BC, Lorentzen JC, Bucht A. Adjuvant oil induces waves of arthritogenic lymph node cells prior to arthritis onset. Clin Exp Immunol. 2004;137(1):59–64.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Wester L, Koczan D, Holmberg J, et al. Differential gene expression in pristane-induced arthritis susceptible DA versus resistant E3 rats. Arthritis Res Ther. 2003;5(6):R361–72.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Vingsbo C, Sahlstrand P, Brun JG, Jonsson R, Saxne T, Holmdahl R. Pristane-induced arthritis in rats a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. Am J Pathol. 1996;149(5):9.Google Scholar
  32. 32.
    Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009;30(9):455–64.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    De Franco M, Peters LC, Correa MA, et al. Pristane-induced arthritis loci interact with the Slc11a1 gene to determine susceptibility in mice selected for high inflammation. PLoS ONE. 2014;9(2):e88302.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Barker RN, Easterfield AJ, Allen RF, Wells AD, Elson CJ, Thompson SJ. B- and T-cell autoantigens in pristane-induced arthritis. Immunology. 1996;89:6.CrossRefGoogle Scholar
  35. 35.
    Holmberg J, Tuncel J, Yamada H, Lu S, Olofsson P, Holmdahl R. Pristane, a Non-antigenic adjuvant, induces MHC class II-restricted, arthritogenic T cells in the rat. J Immunol. 2006;176(2):1172–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Morgan R, Wu B, Song Z, Wooley PH. Immune reactivity to connective tissue antigens in pristane induced arthritis. J Rheumatol. 2004;31:10.Google Scholar
  37. 37.
    Zhu W, Jiang C, Xu J, et al. Pristane primed rat T cells enhance TLR3 expression of fibroblast-like synoviocytes via TNF-alpha initiated p38 MAPK and NF-kappaB pathways. Clin Immunol. 2015;156(2):141–53.CrossRefPubMedGoogle Scholar
  38. 38.
    Vingsbo C, Sahistrand P, Brun JG, Jonsson R, Saxne T, Holmdahl R. Avridine-induced arthritis in rats; a T cell-dependent chronic disease influenced both by MHC genes and by non-MHC genes. Clin Exp Immunol. 1995;99(3):359–63.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Kaibara N, Hotokebuchi T, Takagishi K, et al. Pathogenic difference between collagen arthritis and adjuvant arthritis. J Exp Med. 1984;159:9.CrossRefGoogle Scholar
  40. 40.
    Ratkay LG, Zhang L, Tonzetich J, Waterfield JD. Complete Freund’s adjuvant induces an earlier and more severe arthritis in MRL-ipr mice. J Immunol. 1993;151(1):5081–7.PubMedGoogle Scholar
  41. 41.
    Kleinau S, Erlandsson H, Klareskog L. Percutaneous exposure of adjuvant oil causes arthritis in DA rats. Clin Exp Immunol. 1994;96(2):281–4.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Svelander L, Müssener A, Erlandsson-Harris H, Kleinau S. Polyclonal Thl cells transfer oil-induced arthritis. Immunology. 1994;91(2):260–5.CrossRefGoogle Scholar
  43. 43.
    Lorentzen JC, Glaser A, Jacobsson L, et al. Identification of rat susceptibility loci for adjuvant-oil-induced arthritis. Proc Natl Acad Sci USA. 1998;95:5.CrossRefGoogle Scholar
  44. 44.
    Holm BC, Xu HW, Jacobsson L, Larsson A, Luthman H, Lorentzen J. Rats made congenic for Oia3 on chromosome 10 become susceptible to squalene-induced arthritis. Hum Mol Gen. 2001;10(6):565–72.CrossRefPubMedGoogle Scholar
  45. 45.
    Carlson BC, Jansson AM, Larsson A, Bucht A, Lorentzen JC. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol. 2000;156:2057–65.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Satoh M, Richards HB, Shaheen VM, et al. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin Exp Immunol. 2000;121:399–405.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Richards HB, Satoh M, Shaw M, Libert C, Poli V, Reeves WH. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med. 1998;188(5):6.CrossRefGoogle Scholar
  48. 48.
    Satoh M, Kumar A, Kanwar YS, Reeves WH. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci USA. 1995;92(24):10934–8.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Feng D, Yang L, Bi X, Stone RC, Patel P, Barnes BJ. Protection of Irf5-deficient mice from pristane-induced lupus involves altered cytokine production and class switching. Eur J Immunol. 2012;42(6):1477–87.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Richards HB, Satoh M, Jennette JC, Okano T, Kanwar YS, Reeves WH. Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice. Clin Exp Immunol. 1999;115(3):547–53.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Perry D, Sang A, Yin Y, Zheng YY, Morel L. Murine models of systemic lupus erythematosus. J Biomed Biotechnol. 2011;2011:1–19.CrossRefGoogle Scholar
  52. 52.
    Summers SA, Odobasic D, Khouri MB, et al. Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane. Clin Exp Immunol. 2014;176:342–50.CrossRefGoogle Scholar
  53. 53.
    Clynes R, Calvani N, Croker PB, Richards HB. Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors. Clin Exp Immunol. 2005;141:230–7.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Bagavant H, Nandula SR, Kaplonek P, Rybakowska PD, Deshmukh US. Alum, an aluminium based adjuvant, induces Sjögren’s syndrome-like disorder in mice. Clin Exp Rheumatol. 2014;32(2):251–5.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Kong YC, Audibert F, Giraldo AA, Rose NR, Chedid L. Effects of natural or synthetic microbial adjuvants on induction of autoimmune thyroiditis. Infect Immun. 1985;49:40–5.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Blank M, Krause I, Fridkin M, et al. Bacterial induction of autoantibodies to β2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest. 2002;109(6):797–804.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Zivkovic I, Stojanovic M, Petrusic V, Inic-Kanada A, Dimitrijevic L. Induction of APS after TTd hyper-immunization has a different outcome in BALB/c and C57BL/6 mice. Am J Reprod Immunol. 2011;65(5):492–502.CrossRefPubMedGoogle Scholar
  58. 58.
    Petrusic V, Zivkovic I, Muhandes L, Dimitrijevic R, Stojanovic M, Dimitrijevic L. Infection-induced autoantibodies and pregnancy related pathology: an animal model. Reprod Fertil Dev. 2014;26(4):578–86.CrossRefPubMedGoogle Scholar
  59. 59.
    Petrusic V, Todorovic N, Zivkovic I, et al. Autoantibody response and pregnancy-related pathology induced by combined LPS and tetanus toxoid hyperimmunization in BALB/c and C57BL/6 mice. Autoimmunity. 2015;48(2):87–99.CrossRefPubMedGoogle Scholar
  60. 60.
    Koppang EO, Bjerkas I, Haugarvoll E, et al. Vaccination-induced systemic autoimmunity in farmed Atlantic salmon. J Immunol. 2008;181(7):4807–14.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Jiram Torres Ruiz
    • 1
    • 2
  • Luis Luján
    • 3
  • Miri Blank
    • 2
  • Yehuda Shoenfeld
    • 2
    • 4
  1. 1.Department of Immunology and RheumatologyInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico CityMexico
  2. 2.The Zabludowicz Center for Autoimmune DiseasesSheba Medical CenterTel-HashomerIsrael
  3. 3.Department of Animal PathologyZaragoza UniversitySaragossaSpain
  4. 4.Incumbent of the Laura Schwartz Kipp Chair for Research of Autoimmune DiseasesTel-Aviv UniversityTel-AvivIsrael

Personalised recommendations